Erick Lucera
Erick Lucera's purchase track record
Erick Lucera has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/14/2024 | XAIR | $16K | +20.8% | -7.5% | +10.9% |
| 3/16/2023 | XAIR | $14K | -11.5% | -53.7% | +13.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Beyond Air Affirms FY2027 Sales Guidance at $16‑18M. Beyond Air Inc. (XAIR) confirmed its FY2027 sales guidance at $16‑18 million, matching the $16.715 million estimate from analysts. The company also reported preliminary Q2 revenue of about $2.3 million and reiterated the same FY2026 revenue range of $16‑18 million. These updates suggest the firm is on track to meet its projected sales targets for the next few years.
Transaction History
| DYN | ▼ Sell | Open Market | 1,797 | $47K | 8/13/2026 | View on chart |
| DYN | ▼ Sell | Open Market | 2,362 | $48K | 6/25/2026 | View on chart |
| DYN | ▼ Sell | Open Market | 1,448 | $27K | 5/13/2026 | View on chart |
| DYN | ▼ Sell | Open Market | 5,727 | $107K | 4/1/2026 | View on chart |
| DYN | ▲ Buy | Grant | 65,000 | $0 | 2/12/2026 | View on chart |
| DYN | ▲ Buy | Grant | 66,100 | $0 | 3/31/2025 | View on chart |
| EDIT | ▼ Sell | Open Market | 4,109 | $7K | 3/4/2025 | View on chart |
| XAIR | ▲ Buy | Open Market | 39,266 | $16K | 8/14/2024 | View on chart |
| EDIT | ▼ Sell | Open Market | 22,337 | $125K | 5/20/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 25,966 | $0 | 3/2/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 35,300 | $0 | 3/2/2024 | View on chart |
| EDIT | ▲ Buy | Grant | 77,900 | $0 | 5/17/2023 | View on chart |
| XAIR | ▲ Buy | Open Market | 2,000 | $14K | 3/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Dyne Therapeutics highlighted in recent healthcare stock coverage
Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.
Dyne Therapeutics highlighted in recent healthcare stock coverage. Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.